Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

Presentation TCT 2016

Delivery System and Therapeutic Challenges and Opportunities in Africa

Presenter: Graham A. Cassel, Harun A Otieno

November 01, 2016

Presentation TCT 2016

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Presenter: William A. Gray, Stephan Windecker, Michael Argenziano

October 31, 2016

Presentation Fellows 2016

Antithrombin Pharmacology for the Interventionalist

Presenter: Jeffrey W. Moses, David J. Cohen

April 16, 2016

Presentation Fellows 2016

Rationale for Revascularization in Stable Ischemic Heart Disease

Presenter: Ajay Kirtane

April 15, 2016

Presentation Intravascular Coronary Imaging and Physiology 2016

CT Imaging in Ischemic Heart Disease: CTA, CT-FFR, and CT-Perfusion – Current Uses and Future Projections

Presenter: Nathaniel Reichek

March 10, 2016

Presentation

Effect of PCI on Long-term Survivalin Patients With Stable Ischemic Heart Disease

Presenter: Steven P. Sedlis

November 10, 2015

Presentation TCT 2015

TCT 32: Percutaneous Ventricular Restoration (PVR) Therapy Using the Parachute Device in Patients With Ischemic Dilated Heart Failure Two-Year Results of the PARACHUTE III European Postmarket Trial

Presenter: John P. Cheatham, Carlos Pedra, Ulrich Schaefer

October 13, 2015

Presentation TCT 2015

Ischemic Heart Disease and Acute Coronary Syndrome

Presenter: Hugh J. Linnehan, Bernard J. Gersh

October 13, 2015

Presentation TCT 2015

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

Presenter: Bernard J. Gersh, Stephen D. Wiviott, Giora Weisz

October 13, 2015

Presentation TCT 2015

The Netherlands Presents: A Case Demonstration of Coronary Flow Capacity to Document Ischemic Heart Disease

Presenter: Morton J. Kern, Jan J. Piek, Tim P. van de Hoef

October 12, 2015

Presentation TCT 2015

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? Yes, an Evidence-Based Position!

Presenter: Kevin J. Beatt, Craig R. Smith, Gregg W. Stone

October 11, 2015

Presentation TCT 2015

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? The Data Says Not as a First-Line Therapy!

Presenter: Kevin J. Beatt, Craig R. Smith, David J. Maron

October 11, 2015

Presentation

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

Presenter: BM. Everett BM

August 14, 2015

Presentation Fellows 2015

Rationale for Revascularization in Stable Ischemic Heart Disease

Presenter: Jeffrey W. Moses, Manish A. Parikh, Ajay J. Kirtane

May 16, 2015

Presentation Cardiovascular Interventions 2014

Stem Cells for Ischemic Heart Disease

Presenter: Richard A. Shatz

October 23, 2014

Presentation

Impact of the System and Physician Factors on the Detection of Obstructive CAD with Diagnostic Angiography in Stable Ischemic Heart Disease

Presenter: Harindra C. Wijeysundera

September 11, 2014

Presentation

Heparin Monotherapy or Bivalirudin During PCI in NSTE-ACS or Stable Ischemic Heart Disease

Presenter: Sripal Bangalore

April 22, 2014

Presentation Fellows 2014

Rationale for Revascularization in Stable Ischemic Heart Disease

Presenter: Ajay Kirtane

April 13, 2014

Presentation PCI Outcomes 2014

PCI vs. Optimal Medical Therapy in Stable Ischemic Heart Disease: Has the Last Year Brought More Clarity or Confusion?

Presenter: Ajay J. Kirtane

March 28, 2014

Presentation Cell Therapy 2014

MEta-Analysis of Stem Cell Studies (MESS) In Ischemic Heart Disease Using Patient-Specific Data

Presenter: Mariann Gy?ngy?si

January 23, 2014

Advertisement

Delivery System and Therapeutic Challenges and Opportunities in Africa

Trial #7 - The Essentials ofCTSN SMR Trial - Two-Year Outcomes Following Mitral Valve Repair or Replacement for Severe Ischemic Mitral Regurgitation

Antithrombin Pharmacology for the Interventionalist

Rationale for Revascularization in Stable Ischemic Heart Disease

CT Imaging in Ischemic Heart Disease: CTA, CT-FFR, and CT-Perfusion – Current Uses and Future Projections

Effect of PCI on Long-term Survivalin Patients With Stable Ischemic Heart Disease

TCT 32: Percutaneous Ventricular Restoration (PVR) Therapy Using the Parachute Device in Patients With Ischemic Dilated Heart Failure Two-Year Results of the PARACHUTE III European Postmarket Trial

Ischemic Heart Disease and Acute Coronary Syndrome

Adjuvant Pharmacotherapy With Ranolazine In Patients With Ischemic Heart Disease

The Netherlands Presents: A Case Demonstration of Coronary Flow Capacity to Document Ischemic Heart Disease

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? Yes, an Evidence-Based Position!

Debate: Should Most Patients With Stable Ischemic Heart Disease, Moderate or Greater Ischemia, and Controllable Symptoms Undergo Revascularization? The Data Says Not as a First-Line Therapy!

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

Rationale for Revascularization in Stable Ischemic Heart Disease

Stem Cells for Ischemic Heart Disease

Impact of the System and Physician Factors on the Detection of Obstructive CAD with Diagnostic Angiography in Stable Ischemic Heart Disease

Heparin Monotherapy or Bivalirudin During PCI in NSTE-ACS or Stable Ischemic Heart Disease

Rationale for Revascularization in Stable Ischemic Heart Disease

PCI vs. Optimal Medical Therapy in Stable Ischemic Heart Disease: Has the Last Year Brought More Clarity or Confusion?

MEta-Analysis of Stem Cell Studies (MESS) In Ischemic Heart Disease Using Patient-Specific Data

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content